EN | TR
E-ISSN: 3061-9947
Expression of CD10, BCL-6 and MUM-1 Markers and Their Effects on Prognosis in Diffuse Large B Cell Lymphoma
PDF
Cite
Share
Request
Original Article
VOLUME: 54 ISSUE: 2
P: 189-197
2021

Expression of CD10, BCL-6 and MUM-1 Markers and Their Effects on Prognosis in Diffuse Large B Cell Lymphoma

Acta Haematol Oncol Turc 2021;54(2):189-197
DOI: 10.5505/aot.2021.35403
Ahmet Yozgat 1
Benan Kasapoğlu 2
Nalan Akyürek 3
Aytuğ Üner 4
1. Ufuk University, Faculty of Medicine, Gastroenterology Department, Ankara, Turkey
2. Lokman Hekim University, Faculty of Medicine, Gastroenterology Department, Ankara, Turkey
3. Gazi Üniversitesi Faculty of Medicine, Pathology Department, Ankara, Türkiye
4. Gazi Üniversitesi Faculty of Medicine, Medical Oncology Department, Ankara, Türkiye
5.
No information available.
No information available
Received Date: 2020-05-11T18:29:02
Accepted Date: 2021-08-11T08:35:15
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Immunohistochemistry may serve as a surrogate to define Diffuse large B-cell lymphoma (DLBCL) cases as germinal center B cell-like (GCB) or non-GCB subtypes and to provide prognostic information. In this study, we aimed to investigate the frequency and prognostic impact of CD10, B-cell lymphoma 2 and 6 (BCL2 and BCL6) and multiple myeloma oncogene 1 (MUM1) expressions in pathology sections of patients with DLBCL to determine the response of these subgroups to the rituximab including chemotherapy regimens.

METHODS

Patients were grouped into 2 regarding the chemotherapy regimens they were treated, as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or Rituximab-CHOP. The treatment response, follow-up periods and outcomes of patients were recorded. The immunohistochemical panel was stained in pathology sections for CD10, BCL6 and MUM1/IRF 4 biomarkers. The patients were subgrouped as GCB or ABC regarding the immunohistochemical panel.

RESULTS

Totally 81 patients, (39 male, 42 female) were included in the study. At the time of diagnosis, CD10 was positive in 31 patients (38.3%); BCL-6 in 53 patients (65.4%); MUM-1 was positive in 47 patients (58%) and BCL-2 was positive in 53 patients (65.4). With these results, 36 patients (44.4%) were in the GCB group and 45 patients (55.6%) were in the ABC group. No significant difference was found between the individual markers and subgroups in survival analyses.

DISCUSSION AND CONCLUSION

We did not determine any significant effect of CD10, BCL-6, MUM-1 or BCL-2 positivity or GCB and non-GCB groups in the survival of patients with DLBCL.